Valneva SE announced optimisation of its organisational footprint in France as part of the company’s ongoing efforts to increase operational effectiveness and position Valneva for long-term success.

The company plans to concentrate its French operations at its Lyon location, closing the site in Nantes, which currently includes operational as well as certain pre-clinical research and development (R&D) activities. This consolidation will streamline operations and improve efficiency in France, while also centralising all R&D activities at the company’s site in Vienna.

Valneva plans to relocate its registered office back to Lyon, where it was originally established, and maintain its listing on Euronext Paris. The city of Lyon in France is internationally recognised as a leading vaccine hub, home to major players such as Sanofi Pasteur and the Mérieux group, making it an ideal location for Valneva to concentrate its French operations.

Valneva is committed to support employees throughout this transition and providing assistance to ensure a smooth process for all impacted team members.